In addition, in silico analyses of publicly available genomic datasets of metastatic prostate cancer (including NEPCs) showed rare, mostly nonpathogenic, single-nucleotide variants and one case with a CTSE-ALK fusion (Supplementary Fig. S9 and S10). This evidence concerns the gene ALK and metastatic prostate carcinoma.